Free Trial

Biogen (BIIB) Stock Forecast & Price Target

$226.40
+1.15 (+0.51%)
(As of 05:35 PM ET)

Biogen - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 26 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 9 have given a hold rating, and 17 have given a buy rating for BIIB.

Consensus Price Target

$286.00
26.33% Upside
High Forecast$373.00
Average Forecast$286.00
Low Forecast$200.00

According to the 26 analysts' twelve-month price targets for Biogen, the average price target is $286.00. The highest price target for BIIB is $373.00, while the lowest price target for BIIB is $200.00. The average price target represents a forecasted upside of 26.33% from the current price of $226.40.

TypeCurrent Forecast
7/20/23 to 7/19/24
1 Month Ago
6/20/23 to 6/19/24
3 Months Ago
4/21/23 to 4/20/24
1 Year Ago
7/20/22 to 7/20/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
17 Buy rating(s)
18 Buy rating(s)
21 Buy rating(s)
Hold
9 Hold rating(s)
9 Hold rating(s)
9 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$286.00$286.50$295.58$330.19
Forecasted Upside26.33% Upside27.54% Upside28.45% Upside19.37% Upside
Get Biogen Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Biogen Stock vs. The Competition

TypeBiogenMedical CompaniesS&P 500
Consensus Rating Score
2.65
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside26.33% Upside3,363.24% Upside9.98% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/12/2024Piper Sandler
2 of 5 stars
 Lower TargetOverweight ➝ Overweight$335.00 ➝ $313.00+32.18%
7/3/2024William Blair
2 of 5 stars
 Reiterated RatingOutperform
6/28/2024Needham & Company LLC
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$294.00 ➝ $294.00+28.54%
6/26/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$317.00 ➝ $317.00+41.11%
5/23/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$300.00 ➝ $300.00+33.21%
5/16/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$340.00 ➝ $340.00+48.35%
5/3/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$339.00 ➝ $342.00+57.23%
4/29/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00+24.58%
4/25/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$215.00 ➝ $200.00-1.27%
4/25/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$213.00 ➝ $215.00+6.44%
4/17/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$250.00 ➝ $214.00+11.37%
4/12/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$280.00 ➝ $260.00+27.65%
4/11/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$270.00 ➝ $240.00+19.08%
2/22/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$355.00 ➝ $277.00+25.31%
2/20/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Schmidt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$311.00+43.02%
2/20/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$310.00 ➝ $305.00+39.35%
2/14/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$333.00 ➝ $316.00+42.91%
2/14/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$295.00 ➝ $285.00+28.15%
2/14/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$315.00 ➝ $240.00+5.89%
2/12/2024Bank Of America (Bofa)
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$290.00 ➝ $280.00+14.82%
1/7/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Shrader
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
12/14/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$315.00 ➝ $287.00+12.30%
12/7/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$283.00+21.01%
11/10/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$361.00 ➝ $373.00+65.93%
8/8/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$282.00 ➝ $275.00+1.39%
7/27/2023Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageSector Outperform$327.00+23.28%
5/11/2023Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$320.00 ➝ $350.00+11.73%
5/1/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$270.00 ➝ $350.00+15.04%
2/16/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$300.00 ➝ $315.00+12.91%
12/1/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$370.00+22.16%
11/30/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$325.00 ➝ $350.00+20.11%
10/26/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$270.00 ➝ $300.00+6.36%
10/26/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$270.00 ➝ $310.00+13.32%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:13 PM ET.

BIIB Forecast - Frequently Asked Questions

What is Biogen's forecast for 2024?

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $286.00, with a high forecast of $373.00 and a low forecast of $200.00.

Should I buy or sell Biogen stock right now?

26 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 9 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BIIB shares.

Does Biogen's stock price have much upside?

According to analysts, Biogen's stock has a predicted upside of 27.04% based on their 12-month stock forecasts.

What analysts cover Biogen?

Biogen has been rated by research analysts at Barclays, HC Wainwright, HSBC, Needham & Company LLC, Oppenheimer, Piper Sandler, Royal Bank of Canada, Truist Financial, Wedbush, and William Blair in the past 90 days.

Do Wall Street analysts like Biogen more than its competitors?

Analysts like Biogen less than other "medical" companies. The consensus rating score for Biogen is 2.65 while the average consensus rating score for "medical" companies is 2.72. Learn more on how BIIB compares to other companies.


This page (NASDAQ:BIIB) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners